We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

PERKIN ELMER CORPORATION

PerkinElmer provides detection technologies to detect and identify diseases, imaging technologies to help visualize s... read more Featured Products: More products

Download Mobile App





PerkinElmer Demonstrates Vanadis NIPT Screening Platform Featuring Groundbreaking cfDNA Technology

By LabMedica International staff writers
Posted on 27 Jul 2022
Print article
Image: The Vanadis NIPT screening platform demonstrated at AACC 2022 (Photo courtesy of PerkinElmer)
Image: The Vanadis NIPT screening platform demonstrated at AACC 2022 (Photo courtesy of PerkinElmer)

PerkinElmer, Inc. (Waltham, MA; USA) will be showcasing complete workflows for laboratories, including automation, instrumentation, and reagents, at the 2022 AACC Clinical Lab Expo.

The PerkinElmer exhibit booth will feature demonstrations of its high-throughput Vanadis NIPT solution that takes all the complexity out of noninvasive prenatal testing, making it accessible to more women – and more cost-effective for laboratories. This breakthrough cell-free DNA (cfDNA) technology eliminates PCR amplification and gene sequencing, making it so easy to use that one laboratory technician can handle 2000 to 20 000 samples per year. Walkaway automation streamlines the process from primary tube to final results. Because the Vanadis system is an easy to use, non-NGS and non-PCR based method, any laboratory can use it.

With Vanadis NIPT, laboratories can screen for the risk of trisomies 21, 18, 13, as well as fetal sex determination. By targeting thousands of chromosomal sequences, the Vanadis system can bring high precision non-invasive prenatal testing to labs, counting an average of 650,000 molecules per chromosome. With Vanadis technology, all the critical steps are automated, starting with pipetting steps to reduce manual errors. Plasma volumes are monitored by camera to avoid contamination by the buffy coat, and samples and reagents are barcoded for complete tracking throughout the workflow. PerkinElmer’s software guides labs through the process, with user-friendly touchscreens, enabling remote workflow management for ease of use. Easy to integrate, the software is designed for LIMS connectivity, reducing manual errors while simplifying data management.

Vanadis is the only NIPT screening platform to enable targeted cfDNA analysis without PCR, instead directly capturing target fragments and labeling them for counting. A proprietary nanofilter plate then captures labeled molecules for imaging, eliminating the need for data-intensive steps such as DNA sequencing, microarrays, and microfluidics.

Related Links:
PerkinElmer, Inc. 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.